Eton Pharmaceuticals (NASDAQ:ETON) Insider David Krempa Sells 37,524 Shares

Eton Pharmaceuticals, Inc. (NASDAQ:ETON) insider David Krempa sold 37,524 shares of the business’s stock in a transaction that occurred on Tuesday, May 26th. The stock was sold at an average price of $31.49, for a total value of $1,181,630.76. Following the sale, the insider directly owned 25,249 shares of the company’s stock, valued at $795,091.01. This represents a 59.78% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website.

David Krempa also recently made the following trade(s):

• On Friday, May 22nd, David Krempa sold 42,797 shares of Eton Pharmaceuticals stock. The stock was sold at an average price of $33.39, for a total value of $1,428,991.83.
• On Wednesday, May 27th, David Krempa sold 19,679 shares of Eton Pharmaceuticals stock. The stock was sold at an average price of $31.47, for a total value of $619,298.13.

Eton Pharmaceuticals Stock Performance

ETON stock opened at $32.40 on Thursday. The firm has a market cap of $887.44 million, a PE ratio of -462.79 and a beta of 0.82. The company has a quick ratio of 0.88, a current ratio of 1.21 and a debt-to-equity ratio of 0.62. The business has a 50 day moving average of $26.59 and a 200-day moving average of $20.03. Eton Pharmaceuticals, Inc. has a 12-month low of $13.09 and a 12-month high of $35.66.

Eton Pharmaceuticals (NASDAQ:ETON) last released its earnings results on Thursday, May 14th. The company reported $0.05 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.10 by ($0.05). The business had revenue of $24.27 million during the quarter, compared to the consensus estimate of $22.31 million. Eton Pharmaceuticals had a negative net margin of 1.70% and a negative return on equity of 5.68%. As a group, sell-side analysts expect that Eton Pharmaceuticals, Inc. will post 0.82 earnings per share for the current year.

Hedge Funds Weigh In On Eton Pharmaceuticals

Several institutional investors and hedge funds have recently bought and sold shares of the company. Bank of America Corp DE grew its holdings in Eton Pharmaceuticals by 37.8% during the first quarter. Bank of America Corp DE now owns 144,367 shares of the company’s stock valued at $3,563,000 after purchasing an additional 39,571 shares during the period. EcoR1 Capital LLC grew its holdings in Eton Pharmaceuticals by 7.0% during the first quarter. EcoR1 Capital LLC now owns 2,171,938 shares of the company’s stock valued at $53,603,000 after purchasing an additional 141,394 shares during the period. Aristides Capital LLC grew its holdings in Eton Pharmaceuticals by 15.2% during the first quarter. Aristides Capital LLC now owns 186,041 shares of the company’s stock valued at $4,591,000 after purchasing an additional 24,605 shares during the period. Bank of Nova Scotia bought a new position in Eton Pharmaceuticals during the first quarter valued at $365,000. Finally, Sei Investments Co. bought a new position in Eton Pharmaceuticals during the first quarter valued at $1,432,000. 27.86% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on the company. Wall Street Zen raised Eton Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Saturday, March 21st. Craig Hallum upped their target price on Eton Pharmaceuticals from $30.00 to $35.00 and gave the company a “buy” rating in a report on Friday, March 20th. Zacks Research lowered Eton Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Friday, April 17th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Eton Pharmaceuticals in a report on Tuesday, April 21st. Finally, HC Wainwright upped their target price on Eton Pharmaceuticals from $52.00 to $57.00 and gave the company a “buy” rating in a report on Friday, May 15th. Three equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $41.00.

Eton Pharmaceuticals Company Profile

Eton Pharmaceuticals, Inc is a specialty pharmaceutical company focused on developing, manufacturing and commercializing generic and proprietary pharmaceutical products for patients with rare and underserved diseases. Headquartered in West Palm Beach, Florida, the company leverages its expertise in hormone therapies and complex molecules to address treatment areas where patient need is high and competition is limited. Since its founding in 2016, Eton has sought to build a diversified portfolio that combines established generic medicines with targeted branded offerings.

The company’s product lineup includes thyroid hormone replacements such as desiccated thyroid and liothyronine, as well as pyrimethamine tablets indicated for toxoplasmosis.